KZR Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Kezar Life Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.78 |
52 Week High | US$3.13 |
52 Week Low | US$0.67 |
Beta | 0.47 |
1 Month Change | -1.78% |
3 Month Change | -6.85% |
1 Year Change | -74.31% |
3 Year Change | -85.68% |
5 Year Change | -92.16% |
Change since IPO | -95.63% |
Recent News & Updates
Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14Shareholder Returns
KZR | US Biotechs | US Market | |
---|---|---|---|
7D | -1.7% | 0.7% | 1.2% |
1Y | -74.3% | 5.0% | 27.7% |
Return vs Industry: KZR underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: KZR underperformed the US Market which returned 26% over the past year.
Price Volatility
KZR volatility | |
---|---|
KZR Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: KZR's share price has been volatile over the past 3 months.
Volatility Over Time: KZR's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 58 | Chris Kirk | www.kezarlifesciences.com |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. Fundamentals Summary
KZR fundamental statistics | |
---|---|
Market cap | US$56.05m |
Earnings (TTM) | -US$101.33m |
Revenue (TTM) | US$7.00m |
8.1x
P/S Ratio-0.6x
P/E RatioIs KZR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KZR income statement (TTM) | |
---|---|
Revenue | US$7.00m |
Cost of Revenue | US$77.15m |
Gross Profit | -US$70.15m |
Other Expenses | US$31.18m |
Earnings | -US$101.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.39 |
Gross Margin | -1,002.17% |
Net Profit Margin | -1,447.56% |
Debt/Equity Ratio | 6.0% |
How did KZR perform over the long term?
See historical performance and comparison